Results were published in July 2021 and demonstrated that nivolumab plus chemotherapy resulted in significant improvements in overall survival (OS) (14.4 vs. 11.1 months, hazard ratio (HR) = 0.71, 98.4% CI, 0.59–0.86, p < 0.0001) and progression-free survival (PFS) (7.7 vs. 6.05 months, HR = 0.68, 98% CI, 0.56–0.81, p < 0.0001) when compared with chemotherapy alone in PD-L1 CPS ≥5 GC/GEJC/esophageal adenocarcinoma patients (9). This evidence concerns the gene CD274 and gastric cancer.